• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5073446)   Today's Articles (176)
For: Ballow CH, Jones RN, Biedenbach DJ. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002;43:75-83. [PMID: 12052632 DOI: 10.1016/s0732-8893(01)00334-0] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Number Cited by Other Article(s)
1
Shi X, Wu Y, Ni H, Guo M, Cheng Q, Xu Y. Efficacy and Safety of Different Antibiotic Therapies for Bone and Joint Infections: A Network Meta-analysis of Randomized Controlled Trials. Curr Pharm Des 2023;29:2313-2322. [PMID: 37861039 DOI: 10.2174/0113816128236536231010051130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Revised: 05/10/2023] [Accepted: 06/08/2023] [Indexed: 10/21/2023]
2
Shariati A, Dadashi M, Chegini Z, van Belkum A, Mirzaii M, Khoramrooz SS, Darban-Sarokhalil D. The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2020;9:56. [PMID: 32321574 PMCID: PMC7178749 DOI: 10.1186/s13756-020-00714-9] [Citation(s) in RCA: 93] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Accepted: 03/31/2020] [Indexed: 12/16/2022]  Open
3
Kulkarni RM, Hanagadakar MS, Malladi RS, Santhakumari B, Nandibewoor ST. Oxidation of linezolid by permanganate in acidic medium: Pd(II) catalysis, kinetics and pathways. PROGRESS IN REACTION KINETICS AND MECHANISM 2016. [DOI: 10.3184/146867816x14696298762238] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
4
Kinoshita S, Wada K, Matsuda S, Kuwahara T, Sunami H, Sato T, Seguchi O, Yanase M, Nakatani T, Takada M. Interaction between Warfarin and Linezolid in Patients with Left Ventricular Assist System in Japan. Intern Med 2016;55:719-24. [PMID: 27041154 DOI: 10.2169/internalmedicine.55.5756] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]  Open
5
Tammaro L, Saturnino C, D'Aniello S, Vigliotta G, Vittoria V. Polymorphic solidification of Linezolid confined in electrospun PCL fibers for controlled release in topical applications. Int J Pharm 2015;490:32-8. [PMID: 25934427 DOI: 10.1016/j.ijpharm.2015.04.070] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2014] [Revised: 02/19/2015] [Accepted: 04/24/2015] [Indexed: 11/29/2022]
6
Bassetti M, Cadeo B, Villa G, Sartor A, Cainero V, Causero A. Current antibiotic management of prosthetic joint infections in Italy: the ‘Udine strategy’. J Antimicrob Chemother 2014;69 Suppl 1:i41-5. [DOI: 10.1093/jac/dku251] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]  Open
7
Mendes RE, Deshpande LM, Jones RN. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat 2014;17:1-12. [PMID: 24880801 DOI: 10.1016/j.drup.2014.04.002] [Citation(s) in RCA: 157] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
8
Sacar S, Sacar M, Kaleli I, Toprak S, Cevahir N, Teke Z, Asan A, Sahin B, Baltalarli A, Turgut H. Linezolid compared with vancomycin for the prevention of methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis vascular graft infection in rats: A randomized, controlled, experimental study. Curr Ther Res Clin Exp 2014;68:23-31. [PMID: 24678116 DOI: 10.1016/j.curtheres.2007.02.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/01/2006] [Indexed: 10/23/2022]  Open
9
Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2014;2:51-9. [PMID: 15482171 DOI: 10.1586/14787210.2.1.51] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
10
Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries. J Chemother 2013;24:328-37. [DOI: 10.1179/1973947812y.0000000039] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
11
Millán L, Cerdá P, Rubio MC, Goñi P, Canales M, Capilla S, Oca M, Gómez-Lus R. In VitroActivity of Telithromycin, Quinupristin/Dalfopristin, Linezolid and Comparator Antimicrobial Agents AgainstStaphylococcus aureusClinical Isolates. J Chemother 2013;16:230-7. [PMID: 15330317 DOI: 10.1179/joc.2004.16.3.230] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
12
Linezolid Versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Keratitis in Rabbits. Cornea 2013;32:1052-7. [DOI: 10.1097/ico.0b013e3182912ffa] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
13
Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. Diagn Microbiol Infect Dis 2013;76:206-13. [DOI: 10.1016/j.diagmicrobio.2013.01.025] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2012] [Accepted: 01/31/2013] [Indexed: 12/18/2022]
14
Abe S, Chiba K, Cirincione B, Grasela TH, Ito K, Suwa T. Population Pharmacokinetic Analysis of Linezolid in Patients With Infectious Disease: Application to Lower Body Weight and Elderly Patients. J Clin Pharmacol 2013;49:1071-8. [DOI: 10.1177/0091270009337947] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
15
Rodríguez-Vidigal FF, Nogales-Muñoz N, Vera-Tomé A, Muñoz-Sanz A. Linezolid, Staphylococcus coagulasa-negativa y el problema de las resistencias. Med Clin (Barc) 2012;139:553-4. [DOI: 10.1016/j.medcli.2012.03.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2012] [Accepted: 03/29/2012] [Indexed: 11/28/2022]
16
An assessment of linezolid utilization in selected canadian provinces. CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY 2011;17:177-82. [PMID: 18418496 DOI: 10.1155/2006/818535] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2005] [Accepted: 04/06/2006] [Indexed: 11/17/2022]
17
Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program. Diagn Microbiol Infect Dis 2010;68:459-67. [DOI: 10.1016/j.diagmicrobio.2010.09.018] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2010] [Accepted: 10/23/2010] [Indexed: 11/20/2022]
18
Saleh M, Jehl F, Dory A, Lefevre S, Prevost G, Gaucher D, Sauer A, Speeg-Schatz C, Bourcier T. Ocular penetration of topically applied linezolid in a rabbit model. J Cataract Refract Surg 2010;36:488-92. [PMID: 20202550 DOI: 10.1016/j.jcrs.2009.09.036] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2009] [Revised: 09/25/2009] [Accepted: 09/25/2009] [Indexed: 11/28/2022]
19
Barton E, MacGowan A. Future treatment options for Gram-positive infections--looking ahead. Clin Microbiol Infect 2010;15 Suppl 6:17-25. [PMID: 19917023 DOI: 10.1111/j.1469-0691.2009.03055.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
20
Farrell DJ, Mendes RE, Ross JE, Jones RN. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis 2010;65:392-403. [PMID: 19913682 DOI: 10.1016/j.diagmicrobio.2009.10.011] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2009] [Accepted: 10/20/2009] [Indexed: 10/20/2022]
21
Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD. Zyvox® Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagn Microbiol Infect Dis 2009;65:404-13. [DOI: 10.1016/j.diagmicrobio.2009.10.001] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2009] [Accepted: 10/04/2009] [Indexed: 10/20/2022]
22
Wang JL, Hsueh PR. Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin Pharmacother 2009;10:785-96. [PMID: 19351228 DOI: 10.1517/14656560902811811] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
23
Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis 2009;64:191-201. [PMID: 19500528 DOI: 10.1016/j.diagmicrobio.2009.03.001] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2009] [Accepted: 03/04/2009] [Indexed: 01/06/2023]
24
Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 2009;62:416-26. [PMID: 19022153 DOI: 10.1016/j.diagmicrobio.2008.10.010] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2008] [Accepted: 10/15/2008] [Indexed: 10/21/2022]
25
Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother 2007;8:2381-400. [DOI: 10.1517/14656566.8.14.2381] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
26
Jones RN, Fritsche TR, Sader HS, Ross JE. Zyvox® Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 2007;59:199-209. [PMID: 17908617 DOI: 10.1016/j.diagmicrobio.2007.06.001] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2007] [Accepted: 06/06/2007] [Indexed: 10/22/2022]
27
Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007;59:173-9. [PMID: 17574788 DOI: 10.1016/j.diagmicrobio.2007.04.006] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2006] [Revised: 04/17/2007] [Accepted: 04/17/2007] [Indexed: 11/26/2022]
28
Jørgen B, Merckoll P, Melby KK. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area. ACTA ACUST UNITED AC 2007;39:1059-62. [PMID: 17852934 DOI: 10.1080/00365540701466231] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
29
Pope SD, Roecker AM. Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections. Expert Opin Pharmacother 2007;8:1245-61. [PMID: 17563260 DOI: 10.1517/14656566.8.9.1245] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
30
Ross JE, Fritsche TR, Sader HS, Jones RN. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. Int J Antimicrob Agents 2007;29:295-301. [PMID: 17239570 DOI: 10.1016/j.ijantimicag.2006.09.025] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2006] [Revised: 09/25/2006] [Accepted: 09/26/2006] [Indexed: 11/25/2022]
31
Drew RH. Emerging Options for Treatment of Invasive, Multidrug-ResistantStaphylococcus aureusInfections. Pharmacotherapy 2007;27:227-49. [PMID: 17253914 DOI: 10.1592/phco.27.2.227] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
32
Jones RN, Stilwell MG, Hogan PA, Sheehan DJ. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2007;51:1491-3. [PMID: 17210770 PMCID: PMC1855453 DOI: 10.1128/aac.01496-06] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
33
Potoski BA, Adams J, Clarke L, Shutt K, Linden PK, Baxter C, Pasculle AW, Capitano B, Peleg AY, Szabo D, Paterson DL. Epidemiological Profile of Linezolid‐Resistant Coagulase‐Negative Staphylococci. Clin Infect Dis 2006;43:165-71. [PMID: 16779742 DOI: 10.1086/505114] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2005] [Accepted: 03/20/2006] [Indexed: 11/03/2022]  Open
34
Oh WS, Ko KS, Song JH, Lee MY, Park S, Peck KR, Lee NY, Kim CK, Lee H, Kim SW, Chang HH, Kim YS, Jung SI, Son JS, Yeom JS, Ki HK, Woo GJ. High rate of resistance to quinupristin-dalfopristin in Enterococcus faecium clinical isolates from Korea. Antimicrob Agents Chemother 2006;49:5176-8. [PMID: 16304198 PMCID: PMC1315963 DOI: 10.1128/aac.49.12.5176-5178.2005] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]  Open
35
Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 2006;49:5024-32. [PMID: 16304168 PMCID: PMC1315934 DOI: 10.1128/aac.49.12.5024-5032.2005] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
36
Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2005;57:279-87. [PMID: 16326811 DOI: 10.1093/jac/dki437] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
37
Ciulla TA, Comer GM, Peloquin C, Wheeler J. Human vitreous distribution of linezolid after a single oral dose. Retina 2005;25:619-24. [PMID: 16077360 DOI: 10.1097/00006982-200507000-00013] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
38
Eliopoulos GM, Ferraro MJ, Wennersten CB, Moellering RC. In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria. Antimicrob Agents Chemother 2005;49:3034-9. [PMID: 15980394 PMCID: PMC1168641 DOI: 10.1128/aac.49.7.3034-3039.2005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
39
Anderegg TR, Sader HS, Fritsche TR, Ross JE, Jones RN. Trends in linezolid susceptibility patterns: report from the 2002–2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents 2005;26:13-21. [PMID: 15967640 DOI: 10.1016/j.ijantimicag.2005.02.019] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2005] [Accepted: 02/23/2005] [Indexed: 10/25/2022]
40
Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6. [PMID: 15917519 PMCID: PMC1140485 DOI: 10.1128/aac.49.6.2260-2266.2005] [Citation(s) in RCA: 337] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2004] [Revised: 11/08/2004] [Accepted: 02/04/2005] [Indexed: 02/05/2023]  Open
41
Fortún J, Martín-Dávila P, Navas E, Pérez-Elías MJ, Cobo J, Tato M, De la Pedrosa EGG, Gómez-Mampaso E, Moreno S. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005;56:180-5. [PMID: 15911549 DOI: 10.1093/jac/dki148] [Citation(s) in RCA: 150] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
42
Ross JE, Anderegg TR, Sader HS, Fritsche TR, Jones RN. Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn Microbiol Infect Dis 2005;52:53-8. [PMID: 15878443 DOI: 10.1016/j.diagmicrobio.2004.12.013] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2004] [Accepted: 12/21/2004] [Indexed: 11/29/2022]
43
Brauers J, Kresken M, Hafner D, Shah PM. Surveillance of linezolid resistance in Germany, 2001–2002. Clin Microbiol Infect 2005;11:39-46. [PMID: 15649302 DOI: 10.1111/j.1469-0691.2004.01036.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
44
Dibo I, Pillai SK, Gold HS, Baer MR, Wetzler M, Slack JL, Hazamy PA, Ball D, Hsiao CB, McCarthy PL, Segal BH. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J Clin Microbiol 2004;42:1843-5. [PMID: 15071066 PMCID: PMC387622 DOI: 10.1128/jcm.42.4.1843-1845.2004] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
45
Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004;23:113-9. [PMID: 15013035 DOI: 10.1016/j.ijantimicag.2003.11.003] [Citation(s) in RCA: 237] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
46
Eliopoulos GM. Current and new antimicrobial agents. Am Heart J 2004;147:587-92. [PMID: 15077072 DOI: 10.1016/j.ahj.2003.06.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
47
News in Brief. Expert Rev Anti Infect Ther 2004. [DOI: 10.1586/14787210.2.1.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
48
Jones RN, Farrell DJ, Morrissey I. Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2003;47:2696-8. [PMID: 12878545 PMCID: PMC166062 DOI: 10.1128/aac.47.8.2696-2698.2003] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
49
Lomaestro BM. Resistance to linezolid. Are we surprised? How hard should we look? Ann Pharmacother 2003;37:909-11. [PMID: 12773084 DOI: 10.1345/aph.1d032] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]  Open
50
Min SS, Weber DJ, Donovan BJ, Gilligan PH, Cairns BA, Doern GV, Rutala WA. Multidrug-resistant Enterococcus faecium in a patient with burns. Clin Infect Dis 2003;36:1210-1. [PMID: 12715325 DOI: 10.1086/374669] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]  Open
PrevPage 1 of 2 12Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA